Management ChangeJun 29, 2026, 08:31 AM
Tenaya Therapeutics Appoints Eric Hyllengren as CFO
AI Summary
Tenaya Therapeutics announced the appointment of Eric Hyllengren as its new Chief Financial Officer, effective July 13, 2026. Mr. Hyllengren brings over two decades of experience in biotechnology finance, capital markets, and corporate strategy, having previously served as CFO at Zura Bio and Atara Biotherapeutics. In his new role, he will oversee financial strategy, capital allocation, investor relations, and corporate development. Concurrently, Hiro Higa, Senior Vice President, Finance, will retire in the third quarter of 2026 but will remain as a consultant to ensure a smooth transition.
Key Highlights
- Eric Hyllengren appointed Chief Financial Officer, effective July 13, 2026.
- Hyllengren will oversee financial strategy, capital allocation, investor relations, and corporate development.
- He brings over two decades of experience in biotechnology finance and corporate strategy.
- Previously served as CFO at Zura Bio and CFO/COO at Atara Biotherapeutics, executing over $500 million in public financings.
- Hiro Higa, Senior Vice President, Finance, will retire in Q3 2026 after six years.
- Mr. Higa will remain as a consultant to facilitate a smooth transition of finance and accounting functions.
Price Impact
More from TNYA